Investors Buy Stryker (SYK) on Weakness

Traders bought shares of Stryker Corporation (NYSE:SYK) on weakness during trading hours on Thursday. $50.45 million flowed into the stock on the tick-up and $30.31 million flowed out of the stock on the tick-down, for a money net flow of $20.14 million into the stock. Of all equities tracked, Stryker had the 20th highest net in-flow for the day. Stryker traded down ($0.61) for the day and closed at $151.15

SYK has been the topic of a number of research reports. Robert W. Baird upgraded Stryker from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $161.00 to $173.00 in a report on Thursday, November 16th. SunTrust Banks restated a “buy” rating and issued a $161.00 price target on shares of Stryker in a report on Friday, November 17th. Wells Fargo & Company increased their target price on Stryker from $160.00 to $166.00 in a report on Friday, October 27th. Barclays increased their target price on Stryker from $137.00 to $148.00 and gave the company an “underweight” rating in a report on Friday, October 27th. Finally, Oppenheimer reiterated a “hold” rating on shares of Stryker in a report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $152.10.

The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. The company has a market cap of $56,895.34, a PE ratio of 24.09, a price-to-earnings-growth ratio of 2.39 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.02. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same period last year, the company posted $1.39 EPS. The business’s quarterly revenue was up 6.1% on a year-over-year basis. analysts forecast that Stryker Corporation will post 6.47 EPS for the current fiscal year.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares in the company, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.40% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AXA grew its stake in shares of Stryker by 6.5% during the third quarter. AXA now owns 516,156 shares of the medical technology company’s stock valued at $73,304,000 after acquiring an additional 31,375 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Stryker during the third quarter valued at about $538,000. Public Employees Retirement System of Ohio grew its stake in shares of Stryker by 0.3% during the third quarter. Public Employees Retirement System of Ohio now owns 241,591 shares of the medical technology company’s stock valued at $34,311,000 after acquiring an additional 833 shares in the last quarter. Crestwood Advisors Group LLC grew its stake in shares of Stryker by 1.4% during the third quarter. Crestwood Advisors Group LLC now owns 166,336 shares of the medical technology company’s stock valued at $23,623,000 after acquiring an additional 2,260 shares in the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Stryker by 9.3% during the third quarter. Cetera Investment Advisers now owns 4,883 shares of the medical technology company’s stock valued at $689,000 after acquiring an additional 415 shares in the last quarter. Hedge funds and other institutional investors own 74.97% of the company’s stock.

WARNING: “Investors Buy Stryker (SYK) on Weakness” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2017/12/07/investors-buy-stryker-syk-on-weakness.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply